EPWK Holdings Ltd. Announces Receipt of Nasdaq Delisting Notification Letter

EPWK Holdings Ltd.(Nasdaq: EPWK)(the “Company”), a company that connects businesses with great talents through innovative and efficient cloud-sourcing platforms, today announced that the Companyreceived a letter (the “Notification Letter”) from the Listing Qualifications Staff (the “Staff”) ofThe Nasdaq Stock Market, LLC(“Nasdaq”)on November 20, 2025, notifying the Company that, since the Company has not yet filed […]

Rocket Lab Schedules First Dedicated Launch for Japan Aerospace Exploration Agency (JAXA)

(NASDAQ:RKLB), LONG BEACH, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) — Rocket Lab Corporation (Nasdaq: RKLB) (“Rocket Lab” or “the Company”), a global leader in launch services and space systems, today announced the launch window for the first of two dedicated Electron launches with the Japan Aerospace Exploration Agency (JAXA). The mission, named “RAISE And Shine”,

WillScot Announces Investor Conference Schedule for December 2025

(NASDAQ:WSC), SCOTTSDALE, Ariz., Nov. 24, 2025 (GLOBE NEWSWIRE) — WillScot Holdings Corporation (“WillScot” or the “Company”) (Nasdaq: WSC), a leader in innovative temporary space solutions, today announced that it will participate in the following investor conferences: Bank of America Leveraged Finance ConferenceDate: December 2, 2025Location: Boca Raton, Florida Oppenheimer Winter Industrial SummitDate: December 10 &

Eos Energy Successfully Closes $600 Million Convertible Senior Notes Offering and Registered Direct Offering of Common Stock, Enhancing Financial Liquidity and Fueling U.S. Manufacturing Expansion

(NASDAQ:EOSE), EDISON, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) — Eos Energy Enterprises, Inc. (NASDAQ: EOSE) (“Eos” or the “Company”), America's leading innovator in the design, sourcing, and manufacturing of zinc-based long duration energy storage (LDES) systems, manufactured in the United States, announced the closing of its previously announced offering of 1.75% convertible senior notes due

Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th

(NasdaqGM:ETON), DEER PARK, Ill., Nov. 24, 2025 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team, will host a fireside chat at the Piper Sandler 37th Annual Healthcare Conference

Tarsus to Participate in Upcoming Investor Conference

(NASDAQ:TARS), IRVINE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the BTIG 5th Annual Ophthalmology Day on Monday, December 1st, at 10:45 a.m. PT / 1:45 p.m. ET. A live webcast and additional information can be accessed on the events

XMax Inc. Announces US$5 Million Convertible Note Financing

(NASDAQ:XWIN), LOS ANGELES, Nov. 24, 2025 (GLOBE NEWSWIRE) — XMax Inc., a Nevada corporation (“XMax” or the “Company”) (NASDAQ: XWIN) today announced that on November 18, 2025, it entered into a Convertible Promissory Note Purchase Agreement with Billiongold Holding Limited, pursuant to which the Company issued a convertible promissory note in the principal amount of

Paul Mueller Company Announces Expiration of Share Repurchase Program

(PinkSheets:MUEL),(Pinksheets:MUEL), SPRINGFIELD, Mo., Nov. 24, 2025 (GLOBE NEWSWIRE) — Paul Mueller Company (OTC: MUEL) today announced that the tender offer, announced on October 24, 2025, expired on November 21, 2025, with 31,000 shares being tendered for a total of $15,035,000. On November 25, 2025, Computershare, the Depository for the tender offer, will deliver funds to

Onco360(R) Has Been Selected as The National Specialty Pharmacy Partner for HYRNUO(R) (sevabertinib)

LOUISVILLE, Ky., Nov. 24, 2025 (GLOBE NEWSWIRE) — Onco360(R), the nation's leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Bayer Pharmaceuticals for HYRNUO(R) (sevabertinib). The Food and Drug Administration approved HYRNUO for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors

Ultragenyx to Participate in Investor Conferences in December

(NASDAQ:RARE), NOVATO, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced participation in two upcoming investor conferences. Citi's 2025 Global Healthcare Conference (Miami, FL) Tuesday, December 2, 2025, Eric Crombez, M.D.,

Scroll to Top